Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Gemcitabine Plus Cisplatin Single Dose Versus Split Dose in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer After Failure of Anthracyclines and/or Taxanes

This study has been completed.
Sponsor:
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00192101
First received: September 12, 2005
Last updated: November 16, 2007
Last verified: November 2007
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: July 2005
  Estimated Primary Completion Date: No date given